FDC Limited has informed the Exchange regarding a press release dated May 27, 2026, titled "Financial Results".
FDC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
FDC Limited reported strong Q4 FY26 results with revenue of Rs. 585 crores, up 18.9% Y-o-Y, driven by robust growth across all segments. US exports surged 165.1% to Rs. 71 crores as the business overcame earlier challenges. EBITDA more than doubled to Rs. 106 crores with margins expanding from 11.0% to 18.2% due to operational efficiencies. Full-year FY26 revenue stood at Rs. 2,171 crores (3% growth) with EBITDA margin improving from 15.4% to 15.9%. Domestic Formulations, contributing 82% of FY26 sales, showed muted growth of 0.1% due to subdued performance in key brands like Zifi, Electral and Enerzal. The company received US FDA approval for Fluconazole Tablets during the quarter.
The sharp margin improvement and US business recovery signal operational efficiency gains and improved profit-sharing from US partners, which could be positive for near-term stock performance. However, weak domestic formulations growth remains a concern for full-year outlook.